This specific ISBN edition is currently not available.View all copies of this ISBN edition:
The book best written about cancer vaccine for both medical professionals and cancer patients. This book is about cancer vaccines for patients, their families and physicians and the opportunity they offer to improve the cancer treatment.
The results of the research conducted by scientists worldwide to date are promising enough to justify our hope that this book will open your door to cancer vaccines. This book is about a vision for the future; it is about the possibility of a better quality of life for people with cancer. And it is a book about how vaccines can be used to help treat and, hopefully one day, help cure or even prevent cancer.
In short, this book seeks to open the door to cancer vaccines as we zero in on the cancer cell.
"synopsis" may belong to another edition of this title.
Dr. Lowell T. Harmison is the former Deputy Assistant Secretary of Health of the U.S. Public Health Service, Department of Health and Human Services. He has had an extensive career in medical research and public health that began at the National Institutes of Health in Bethesda, Maryland in 1966. A part of his dedicated work over several decades has been to enhance the quality and availability of vaccines as well as their review and approval by regulatory bodies in the U.S., Europe, China and other countries. These vaccine efforts have included work on specific tumor antigens, monoclonal antibodies and tissue extracted tumor antigens complemented with immune stimulators. Also, Dr. Harmison has served as a member of the U.S. DHHS Vaccine Compensation Commission to work out strategies and mechanisms to properly address adverse events caused by vaccines. Dr. Harmison fs commitment to biomedical research and public health extends back over thirty-five years. He has made notable contributions to biomedical research and public health. For example, led the development and testing of the HIV/AIDS blood test for the U.S. Public Health Service to yield the first Blood Test approved by FDA in record time for use by the American Red Cross to screen the American Blood supply. This test prevented the spread of the HIV to hundreds of thousands of individuals in the U.S. and around the world and as a result, prevented an untold number of deaths from AIDS.
Dr. Kenichiro Hasumi is a physician, specialized in cancer immunotherapy and terminal care. He is also a researcher and visionary, focused on the development of cancer vaccines and improved clinical treatments to achieve better patient outcomes with a higher quality of life. He is devoted to his patients and their families, and to improved cancer education, understanding, and awareness on a global scale. In 1931, his late father Dr. Kiichiro Hasumi advanced the hypothesis of cancer propagation by virus and started studies to prove his theory. And after seventeen years of meticulous research and development efforts, the clinical application of the Hasumi Vaccine as the first and most used cancer vaccine in the history of medicine was started and has been clinically used for more than fifty yeas. In 1988, Dr. Hasumi succeeded his father in this pioneering work in order to continue research and development, and the treatment of cancer patients. In 1999, Dr. Hasumi established the Hasumi International Research Foundation (HIRF) as a nonprofit organization in the United States. The primary purpose of HIRF is to conduct and support scientific research in connection with finding a cure for various forms of cancer, particularly with the use of immunotherapy. And currently, with his ever-growing vision to help cancer patients, Dr. Hasumi has been supporting various cancer researches in the United States, Japan, China, and Brazil. HIRF has also been sponsoring the International Cancer Vaccine Symposium since 2001.
"About this title" may belong to another edition of this title.
Book Description Hasumi International Research Foundation, 2002. Hardcover. Condition: New. Seller Inventory # DADAX0972387706